Introduction
Malignant gliomas represent the most common primary brain tumor in adults. These tumors have an extremely aggressive natural history even when treated with combined modality therapy (Nelson et al., 1988; Fine et al., 1993) . This is especially true for glioblastoma multiformes (GBMs) where median survival is less than 1 year and few, if any, cures are achieved (Davis et al., 1998) . Since adjuvant radiation therapy (following resection) is considered standard of care for patients with this diagnosis, the high recurrence rates seen with these brain tumors indicate their relative clinical radioresistance.
While multiple genetic lesions have been correlated with increasing grade of gliomas, overexpression of EGFR is one of the more prominent abnormalities associated with high-grade gliomas. Up to 50% of GBMs display amplification of the EGFR gene while a significant proportion of GBMs without EGFR gene amplification displays overexpression of this receptor (Wong et al., 1987) . Mutant forms of EGFR are commonly associated with amplification in GBMs. The most common and best characterized EGFR mutant (EGFRvIII) results from the deletion of exon 2-7 leading to expression of a truncated receptor that has lost roughly half of its extracellular, ligand-binding domain (Humphrey et al., 1990; Wong et al., 1992) . EGFRvIII no longer binds ligand and displays ligandindependent, constitutive activity (Wong et al., 1992) . Expression of EGFRvIII can increase the tumoriginicity of a glioma cell line (Nagane et al., 1996) and induce tumors in a murine glioma model (Holland et al., 1998) . In addition to its transforming activity, EGFRvIII has been shown to decrease sensitivity to chemotherapeutic agents through a reduction in apoptotic response (Nagane et al., 1998) .
While EGFRvIII has been extensively studied within human glioma cell lines and a variety of murine cells, the effects of its expression in primary human astrocytes have not been well characterized. Primary human astrocytes grow slowly and have a limited number of population doublings before undergoing senescence making them difficult to work with. With the recent identification of human telomerase (hTERT) (Meyerson et al., 1997) , Hahn et al., (1999) reported that sequential introduction of large T antigen (LT) and hTERT into primary human fibroblasts was sufficient to allow these cells to maintain telomeric length and thereby bypass senescence. This immortalization procedure has been found to be adaptable to primary human astrocytes as well (Rich et al., 2001; Sonoda et al., 2001b) . Since immortalized normal human astrocytes can now be handled with the ease of typical glioma cell lines, they are an ideal model system to study the development of malignant gliomas, and to test the effects of EGFRvIII expression.
Given the frequency of EGFRvIII mutations in malignant gliomas relative to other tumors, we hypothesized that this mutant receptor may have differential function in cells of astrocytic origin. In this report, immortalized normal human astrocytes (NHAs) and fibroblasts (NHFs) are used as model systems to determine the differential effect of EGFRvIII expression in astrocytic and non astrocytic cell types. Evaluation of downstream signaling by EGFRvIII in these two cell types revealed that, both cell types displayed ERK activation and increased proliferation. In contrast to ERK activation by EGFRvIII, only NHAs showed activation of the PI-3K pathway by the mutant receptor. Similarly, expression of EGFRvIII in the LN229 glioma cell line also resulted in AKT activation. When response to DNA damage by radiation was assessed, EGFRvIII selectively increased radioresistance only in NHAs. EGFRvIII's ability to increase the radioresistance of immortalized astrocytes appears to be dependent upon activation of the PI-3K/AKT pathway. Thus, cells of astrocytic origin appear to provide a permissive environment for activation of the PI-3K pathway by EGFRvIII.
Results

Construction of immortalized normal human astrocytes and fibroblasts that express EGFRvIII
With the identification of the hTERT gene, it has become possible to restore telomerase activity and maintain the ends of telomeres in primary cells. Hahn et al., (1999) first reported that sequential introduction of LT and hTERT allowed primary human diploid fibroblasts to bypass senescence and proliferate indefinitely in tissue culture. This system has been adapted to allow immortalization of a variety of other cell types including astrocytes (Rich et al., 2001; Sonoda et al., 2001b) . Using this approach, we have independently derived immortalized primary human astrocytes and fibroblasts. LT and hTERT were sequentially introduced into NHAs and NHFs via MuLV-based retroviral vectors that express the neomycin and hygromycin resistance genes, respectively. After selection of the infected astrocytes and fibroblasts in G418 and hygromycin, cell lines were derived that show expression of both LT and hTERT and could divide indefinitely without evidence of undergoing senescence (data not shown).
Owing to the frequency at which EGFRvIII is seen in malignant gliomas, this altered receptor was introduced into our immortalized NHAs as well as NHFs, a nonastrocytic control, to examine its role in the development of phenotypes characteristic of malignant gliomas. EGFRvIII was introduced into these cell lines using the pBABE/puro retroviral vector and was selected in the presence of puromycin. Significant overexpression of the mutant EGFRvIII in the immortalized NHFs and NHAs was confirmed by immunoblot analysis (Figure 1 ). To determine whether this mutant receptor has constitutive activity in these primary cells, immunoblot analysis was also performed using an antibody with specificity against EGFR phosphorylated on tyrosine 1173. In both NHFs and NHAs, significant levels of tyrosine phosphorylated EGFR were detected indicating that the introduced receptor is functional and has constitutive tyrosine kinase activity (Figure 1 ).
EGFRvIII has expanded ability to activate downstream signals in human astrocytes compared with fibroblasts
As EGFRvIII is predominantly found in high-grade glial neoplasms, we hypothesized that signaling downstream of this altered receptor may differ in astrocytes versus other cell types. To determine whether this was the case, we assessed for activation of the PI-3K/AKT and Ras/Raf/MEK/ERK pathways in our cell systems. Immunoblot analysis was performed against AKT and ERK along with their phosphorylated counterparts (P-AKT and P-ERK, respectively). As expected, in both the NHF and NHA cells, the PI-3K and Ras/Raf pathways were activated after the addition of EGF as evidenced by accumulation of P-AKT and P-ERK, respectively (Figure 2a, b) . However, in the absence of ligand, EGFRvIII was still able to activate both pathways in the astrocytes (Figure 2b , lanes 1 and 5) but only the Ras/Raf pathway in the fibroblasts (Figure 2a , lanes 1 and 5). While EGFRvIII was unable to activate AKT in NHFs, the PI-3K pathway is still functional in these cells since addition of EGF leads to significant accumulation of P-AKT (Figure 2a ). To test whether this effect is only present in the human astrocytes or whether it is also present in other cells of astrocytic origin, EGFRvIII was introduced into the LN229 glioma cell line as well. Expression of the mutant receptor was confirmed by immunoblot analysis (Figure 2c ). However, as with the NHAs, the EGFR- Figure 1 EGFRvIII is expressed and active in NHF and NHA. Immunoblots of lysates from NHF/puro (lanes 1 and 5), NHF/ EGFRvIII (lanes 2 and 6), NHA/puro (lanes 3 and 7) and NHA/ EGFRvIII (lanes 4 and 8) resolved by 8% SDS/PAGE. Blots were probed with an anti-EGFR antibody (lanes 1-4) and an antiphospho-EGFR antibody (P-EGFR, lanes 5-8). The solid arrow denotes the position of endogenous, wild-type EGFR and the open arrow denotes the position of EGFRvIII. An actin loading control is included for each blot EGFRvIII signaling and radioresistance in astrocytes B Li et al vIII-expressing LN229 also showed constitutive EGFR activity with detectable autophosphorylation of the truncated receptor as well as activation of both the Ras/Raf pathway and, more importantly, the PI-3K pathway with detectable , respectively, in the absence of ligand (Figure 2c , lanes 1 and 5).
Proliferation of human fibroblasts and astrocytes are both enhanced by EGFRvIII
We next assayed the ability of EGFRvIII to alter the proliferative capacity of our NHF and NHA cell lines overexpressing EGFRvIII. To test this, NHF/EGFRvIII and NHA/EGFRvIII were compared with their corresponding vector only controls and growth rates were measured by serial cell counts as well as by serial MTT assays. Consistent with activation of the Ras/Raf pathway by EGFRvIII in both cell types, proliferation of fibroblasts and astrocytes were increased after expression of this altered receptor (Figure 3a, b) . Next, cell cycle profiles for EGFRvIII-expressing NHF and NHA cell lines and their corresponding vector controls were determined. Consistent with the results of the proliferation assays, fibroblasts and astrocytes expressing EGFRvIII displayed an increase in the percentage of cells in the S and G2/M phases of the cell cycle with a corresponding decrease in the G1 fraction compared with their controls (Figure 3c ).
To prove that EGFRvIII, and the Ras/Raf pathway specifically, is responsible for the increased proliferation seen in the immortalized NHFs and NHAs, EGFRvIII and MEK were both targeted with specific chemical inhibitors. Since the MTT assay used to examine proliferation of NHFs and NHAs was performed in For each cell line, duplicate blots were generated and cut filters were probed with antibodies against total EGFR, AKT and ERK or phosphorylated EGFR (P-EGFR), AKT (P-AKT) and ERK (P-ERK), as noted Figure 3 EGFRvIII expression increases the proliferation and Sphase fraction of both NHFs and NHAs. All assays were performed as described in the Materials and methods section. (a) For the cell count assay, plates 12 (12-well) were initially seeded with 2 Â 10 4 cells. After adherence to the plate for 6 h, the first time point (hour 0) was taken. Cell counts were manually performed on a hemocytometer at the indicated times. All points represent the count from three independent wells and error bars are 71 s.d. (b) For the MTT assay, 2.5 Â 10 3 cells were seeded in 96-well dishes and allowed to grow for a specified number of days under normal culture conditions before assaying with MTT. The Y-axis represent the baseline-corrected OD 570 nM reading and the x-axis represent number of days from initial seeding before performing the MTT assay. Each point represent the average of five independent wells and error bars are 71 s.d. (c) Graph of the cell cycle distribution of NHF and NHA derivatives is shown. Cells were at subconfluent (o80% confluent) when harvested. Results represent the average of three independent plates. Error bars are 71 s.d. Student's t-test was used to compare point between vector controls and EGFRvIIIexpressing cells. Statistically significant differences between points are denoted by the presence of serum, we generated lysates from NHF/ EGFRvIII and NHA/EGFRvIII cells cultured with 10% fetal calf serum treated with the EGFR inhibitor PD153035 and the MEK inhibitor U0126. Of note, under these conditions, the basal level of P-AKT and P-ERK is increased, likely due to the activation of endogenous EGFR by ligand present in serum. PD153035 inhibited signaling to both AKT and ERK as would be expected of an EGFR inhibitor ( Figure 4a , lanes 2 and 5). For the MEK inhibitor U0126, ERK activation was significantly inhibited while AKT activation was largely unaffected (Figure 4a , lanes 3 and 6). These inhibitors were then assessed for their ability to affect the proliferation of matched sets of NHF and NHA. The cell lines were treated with either PD153035 or U0126 in complete growth media for 3 days and then assayed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. When results were normalized with untreated controls, PD153035 appear to decrease proliferation significantly to a greater extent in the EGFRvIII-expressing cells in comparison to the vector controls (Figure 4b) . Similarly, U0126 appear to be trending towards decreasing proliferation more in the EGFRvIII-expressing cells, although this did not reach statistical significance for NHAs (Figure 4b ). The likely explanation as to why U0126 did not affect proliferation differentially in the EGFRvIII cells versus the vector controls to the extent seen with PD153035 is that many other factors are contributing to ERK activation in these lines and this would dilute out the effect of ERK activation by EGFRvIII in these cells.
Expression of EGFRvIII confers radioresistance to human astrocytes but not fibroblasts
Despite high doses of radiation therapy, glioblastoma multiformes (GBMs), the highest grade gliomas, invariably fail therapy and typically recur within an area that received full radiation doses. Thus, these tumors, which commonly express EGFRvIII, display significant clinical radioresistance. We postulated that EGFRvIII may alter the radiosensitivity of these tumors. Since activation of the PI-3K pathway has been shown to confer resistance to radiation therapy (Brognard et al., 2001; Gupta et al., 2001 ) and our data demonstrate that this altered receptor activates AKT selectively in cells of astrocytic origin, we hypothesized that EGFRvIII will produce radioresistance in NHAs but not NHFs. To test this hypothesis, clonogenic survival of matched pairs of vector and EGFRvIII-expressing NHFs and NHAs in response to varying doses of ionizing radiation was determined. As we predicted, EGFRvIII was found to confer radioresistance upon the NHA cell line significantly when irradiation was performed with cells cultured in media containing either 10% or no serum (Figure 5a, b) . However, under these same conditions, expression of EGFRvIII did not lead to a significant change in the radiosensitivity of the NHF cell line (Figure 5a, b) . A potential mechanism by which EGFRvIII promotes radioresistance is by increasing resistance to radiationinduced apoptosis. Therefore, apoptotic response to irradiation was assessed in these cell lines. No difference in the level of apoptosis was found over a range of radiation doses between EGFvIII-expressing cells and their corresponding controls (Figure 5c,d) . Thus, while expression of EGFRvIII appears to increase the radioresistance of astrocytes but not fibroblasts, this differential response did not appear to be mediated by alterations in radiation-induced apoptosis.
Inhibition of PI-3K signaling reverts the EGFRvIIIdependent radioresistant phenotype in immortalized astrocytes
While activation of the PI-3K pathway by EGFRvIII in astrocytes likely plays a role in altering sensitivity to 3) and NHA (lanes 4-6) expressing EGFRvIII are shown. Cells were cultured in 10% fetal calf serum-starved and either treated with DMSO only (lanes 1 and 4), 8 mM PD153035 (lanes 2 and 5) or 35 mM U0126 (lanes 3 and 6) for 72 h. For each cell line, duplicate blots were generated and cut filters were probed with antibodies against AKT and ERK or phosphorylated AKT (P-AKT) and ERK (P-ERK), as noted. (b) MTT assays were performed as previously described. Matched pairs of NHF and NHA (puro and EGFRvIII) cells were treated with DMSO only, PD153035 (7 mM) or U0126 (35 mM) for 72 h one day after initial seeding of 3 Â 10 EGFRvIII signaling and radioresistance in astrocytes B Li et al radiation, other signaling pathways that we have not assessed may be likewise differentially activated in astrocytes versus fibroblasts and account for production of the radioresistant phenotype. Therefore, the relative contribution of the PI-3K pathway to resistance to ionizing radiation in our immortalized astrocytes was tested. The PI-3K inhibitor LY294002 or carrier alone (DMSO) was used to treat our matched pair of NHAs (NHA/puro and NHA/EGFRvIII) at the time of irradiation and clonogenic survival was determined. When cells were only treated with DMSO, NHA/ EGFRvIII cells displayed increased clonogenic survival compared with the corresponding vector control ( Figure 6 ). LY294002 (25 mM) was capable of decreasing PI-3K activity and AKT phosphorylation in NHAs (data not shown). When NHA/EGFRvIII cells were treated with this level of drug, clonogenic survival was lowered to levels seen with either inhibitor-or carriertreated NHA/puro cells ( Figure 6 ).
Discussion
In this paper, we find that EGFRvIII is able to activate AKT in human astrocytes but not fibroblasts. The ability of EGFRvIII to activate the PI-3K pathway was not restricted to normal human astrocytes since we were also able to detect it in the LN229 glioma cell line. Thus, EGFRvIII appears to have the ability to activate the PI-3K/AKT pathway in cells of astrocytic origin. EGFRvIII is a functional kinase in both astrocytes and fibroblasts since ERK can be phosphorylated in the absence of ligand in either cell type. Furthermore, activation of ERK correlates with increased proliferation of both cell types. However, consistent with selective activation of the PI-3K/AKT pathway in astrocytes and this pathway's recognized ability to alter radioresistance, EGFRvIII was able to increase the radioresistance of astrocytes but not fibroblasts. Inhibition of PI-3K activity can revert the radioresistant phenotype of NHA/EGFRvIII cells. Graphs of clonogenic survival of NHA/puro and NHA/vIII (EGFRvIII) treated with DMSO only (ÀLY) or 25 mM LY294002 ( þ LY) for 2 h prior to exposure to radiation are shown. Cells were cultured in 0% serum at the time of irradiation. Curve fitting was performed using a standard linearquadratic model. Results are the average of three independent plates for each point. Error bars are 71 s.d. Statistically significant differences between NHA/vIII points 7LY294002 are denoted by * P-valuep0.05 and **
P-valuep0.01
EGFRvIII signaling and radioresistance in astrocytes B Li et al Based on our results, we believe that EGFRvIIIdependent ERK activation is primarily responsible for the increased proliferative capacity of NHF/EGFRvIII and NHA/EGFRvIII. This appears to contrast with a recent paper by Klingler-Hoffmann et al., (2003) where the authors found that inhibition of the PI-3K pathway through treatment with the chemical inhibitor wortmannin or expression of PTEN tumor suppressor was sufficient to inhibit growth of the U87 glioma cell line expressing deltaEGFR, or EGFRvIII. However, our data do not necessarily conflict with their report. While we show that ERK activation is important for mediating EGFRvIII-dependent proliferation (Figures 3,4) , our data do not eliminate a role for the PI-3K pathway in cellular growth in situations where this pathway becomes activated.
The activation of PI-3K by EGFRvIII in cells of astrocytic origin may explain why this altered receptor is frequently seen in malignant gliomas. While increasing resistance to ionizing radiation does not, on its own, alter the malignancy of these tumors, this radioresistant phenotype may potentially translate into increased tumor cell survival under conditions such as hypoxia that could alter the aggressiveness of these brain malignancies. Consistent with this idea, recent evidence suggest that, in a malignant glioma model system, increased AKT signaling can change an anaplastic astrocytoma (WHO grade III tumor) into a GBM (WHO IV tumor) (Sonoda et al., 2001a) . Moscatello et al., (1995) has reported that EGFRvIII is more prevalent within other tumor types than previously thought through detection with an anti-EGFRvIIIspecific antibody. However, gene rearrangement is not seen in these cases and the altered receptor is instead thought to be produced through an alternative splicing mechanism. Thus, the predominant EGFR species, in these cases, remain the full-length receptor, which differs from the typical situation in malignant gliomas where the truncated receptor is highly overexpressed. Therefore, their results are not necessarily inconsistent with our hypothesis that EGFRvIII has specific activities in astrocytes that contribute to the transformation and malignancy of GBMs but not other tumor types. However, providing greater support for our findings that EGFRvIII has specific activities within astrocytes not seen in other cell types, Jungbluth et al., (2003) found that while increased EGFR expression is seen in a number of tumor types, expression of EGFRvIII is highly specific for malignant gliomas.
We hypothesize that differential downstream signaling by EGFRvIII in astrocytes and fibroblasts accounts for the differential effect on radioresistance. However, like others have found (Sonoda et al., 2001b) , our NHA/ EGFRvIII cell line did not display significant in vitro transformation as assayed by growth in soft agar (data not shown). While EGFRvIII, on its own, appears unable to transform human astrocytes, the effects of this receptor on proliferation and cell survival likely enhance the malignancy of gliomas. Interestingly, Antonyak et al., (1998) has found that in NIH3T3, a mouse fibroblast cell line, EGFRvIII does signal through the PI-3K pathway with detectable accumulation of phosphotidyl inositol 3,4,5-trisphophate (PIP 3 ). However, this activation did not lead to phosphorylation of AKT but appears to activate other signals downstream of PI-3K including Jun kinase (Antonyak et al., 1998) . Narita et al., (2002) has also evaluated downstream signaling from EGFRvIII in the U87 glioma cell line and found that AKT phosphorylation increases as a result of EGFRvIII overexpression. These reports appear to be entirely consistent with our findings that AKT is activated in cells of astrocytic but not fibroblastic origin.
Our finding that EGFRvIII expression in human astrocytes results in increased radioresistance is particularly relevant to malignant gliomas since radiation therapy is a mainstay of treatment for these aggressive brain tumors. Similar to our finding, others have previously shown that expression of EGFRvIII in the U87 glioma cell line results in the induction of resistance to chemotherapy (Nagane et al., 1998) . In the U87 system, resistance to chemotherapy was found to result from induction of Bcl-XL leading to increased resistance to apoptosis (Nagane et al., 1998) . In their model, activation of the PI-3K/AKT pathway leads to induction of the antiapoptotic Bcl-XL as well as other, as yet undefined effectors, that would mediate resistance to apoptosis. However, while EGFRvIII induces radioresistance in astrocytes, we were unable to detect significant differences in radiation-induced apoptotic response between NHA/EGFRvIII cells and its corresponding control ( Figure 5 ). The inability of EGFRvIII to protect either human astrocytes or fibroblasts from apoptosis is supported by the lack of Bcl-X induction in either case (data not shown). While decreased apoptotic response is an attractive explanation for the production of radioresistance in our immortalized NHAs, our data do not support that idea. Tezuka et al., (2001) reported that overexpression of insulin-like growth factor receptor in mouse embryo fibroblasts led to radioresistance as measured by a colony formation assay but no change in radiation-induced apoptosis. Thus, it is possible for a receptor tyrosine kinase to alter radioresistance without affecting the induction of apoptosis by ionizing radiation.
Clearly, EGFRvIII is not affecting radiation-induced apoptotic response in our astrocytes. This contrasts with the report by Nagane et al., (1998) that showed that this altered receptor can affect chemotherapy-induced apoptotic response in the U87 glioma cell line. It is possible that EGFRvIII does not affect radiation-induced apoptosis in our astrocytes because it requires interaction with other alterations that are found in glioma cell lines but not nontransformed astrocytes. One such alteration could be loss of the PTEN/MMAC tumor suppressor. This alteration is often seen in malignant gliomas and glioma cell lines including U87 Steck et al., 1997) . The PTEN tumor suppressor is a lipid phosphatase that opposes the effect of PI-3K (Myers et al., 1997 (Myers et al., , 1998 Maehama and Dixon, 1998; Stambolic et al., 1998; Wu et al., 1998) . PI-3K/AKT signaling by EGFRvIII could be further potentiated in U87 due to loss of PTEN. This may account for the lack of Bcl-X induction seen in our astrocytes versus an established glioma cell line. While we see no difference in the apoptotic response of NHA/puro and NHA/ EGFRvIII cells to radiation, the levels of apoptosis appear to be lower in cells radiated under serum-starved conditions. This result appears surprising on the surface. However, the serum-starved cells are growth arrested, which can influence the extent to which a cell will undergo programmed cell death. While passage through the cell cycle is not a requirement for undergoing this cellular program, it can certainly affect the percentage of cells that initiate this process (for a review, see Vermeulen et al., 2003) .
One attractive mechanism by which EGFRvIII can differentially activate the PI-3K/AKT pathway in cells of astrocytic versus fibroblastic origin involves potential interactions with its family members. EGFR belongs to a family of receptor tyrosine kinases consisting of four members termed erbB1-4 (erbB1 is EGFR). Following ligand binding, various combinations of homo-and hetero-dimers are possible with this receptor family yielding a diverse range of potential signals that can be transmitted downstream. While an initial report suggested that EGFRvIII is not able to dimerize (Chu et al., 1997) , more recent evidence seems to indicate that while loss of a portion of the extracellular, ligand-binding domain in EGFRvIII results in its inability to interact with ligand, enough sequence is retained to allow interactions with itself, and possibly, other family members (Fernandes et al., 2001) . A model where this truncated receptor interacts with other full-length erbB family members could explain our observations. In this model, downstream signaling may differ depending on the relative expression of different erbB family members leading to the formation of differing ratios of various EGFRvIII:erbB heterodimers in astrocytes and fibroblasts. Of note, the NHF cells appear to express higher levels of the endogenous, full-length EGFR than the NHA cells. Thus, it is possible that interactions between wild-type EGFR and EGFRvIII is acting to reduce signaling to AKT.
Given the poor outcomes with these tumors, the search for new therapies remains one of the primary goals for research in this field. Our findings suggest that expression of EGFRvIII may increase radioresistance more in cells of astrocytic origin than in other cell types. Thus, new therapeutics aimed at targeting the EGFR kinase or, even specifically the mutant receptor, may have the potential for increasing response to standard treatments such as radiation therapy. Therefore, these potential new therapies that target EGFRvIII in malignant gliomas should be evaluated not only as single agents but also in concert with more standard cytotoxic therapies such as radiation therapy or chemotherapy.
In summary, we have found differential signaling from a tumor-specific, mutant EGFR in cells of astrocytic and fibroblastic origin. Enhanced signaling through the PI-3K/AKT pathway appears responsible for increasing the radioresistance of immortalized astrocytes and may promote survival under other circumstances as well. The ability of EGFRvIII to induce the radioresistant phenotype selectively in astrocytes likely contributes to radiation therapy treatment failures of malignant gliomas expressing this mutant receptor and may also increase the resistance of these gliomas to cytotoxic therapies. Thus, selective induction of the AKT signal by EGFRvIII within astrocytes may explain why this mutant receptor is frequently associated with malignant gliomas but less commonly with other tumor types.
Materials and methods
Cell lines and growth factor treatment
NHAs were obtained commercially (Clonetics, Cambrex Bioscience, Walkersville, MD, USA) and passaged according to the manufacturer's recommendation. NHFs (kindly provided by R Muschel) and the glioma cell line LN229 were passaged within DME high glucose media (Mediatech, Herndon, VA, USA) containing 10% fetal calf serum (Gibco, Invitrogen Corp., Carlsbad, CA, USA) and penicillin (100 U/ ml)/streptomycin (100 mg/ml). The MuLV-based expression vectors, pBABEneo and pBABEhygro, containing LT (and neomycin-resistant gene) and hTERT (and hygromycinresistant gene) respectively (kindly provided by R Weinberg), were used to sequentially introduce these genes into NHAs and NHFs similar to the method described by Hahn et al. (1999) . Briefly, pantropic, replication-defective viral particles were generated after transient transfection into 293 T cells along with expression vectors for MuLV gag and pol genes as well as the vesicular stomatitis virus G glycoprotein gene (Burns et al., 1993) . These defective retroviral vectors were used sequentially to infect the primary cells of interest. After selection in G418 (400-600 mg/ml) and hygromycin (100 mg/ml), drug-resistant cell lines were generated that expressed LT (confirmed by immunohistochemistry) and hTERT (confirmed by the TRAP assay). After immortalization, NHAs were able to grow well in our standard media (DME with 10% fetal calf serum) and all subsequent experiments were performed using this medium. To express EGFRvIII, immortalized NHAs and NHFs as well as LN229 were infected with the retroviral expression vector, pBABEpuro, containing EGFRvIII prepared as described above. The EGFRvIII-expressing cells were selected for in the presence of puromycin (1 mg/ml). In each case, cell pools were used in the experiments. For the experiment with growth factor treatment, cells were starved for 24 h prior to exposure to epidermal growth factor (EGF) (100 ng/ml) (Discovery Labware, BD Biosciences, Bedford, MA, USA). Cells were then harvested at the indicated times following treatment with EGF.
Immunoblot analyses
All immunoblots were carried out according to standard procedures. Appropriate cells were lysed in RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS, 0.5% deoxycholate) containing a cocktail of protease and phosphatase inhibitors. Total protein concentration was determined by using the Coomassie Plus Protein Assay reagent (Pierce, Rockford, IL, USA) and equal amounts of protein resolved by SDS-PAGE and electrotransferred to PVDF membrane (Bio-Rad, Hercules, CA, USA). Blots were probed with antibodies against EGFR (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phosphorylated EGFR (Upstate Biotechnology, Waltham, MA, USA), AKT/ phosphorylated AKT (Cell Signaling Technology, Beverly, MA, USA) and ERK/phosphorylated ERK (Sigma, St Louis, MO, USA) according to the manufacturer's recommendations. The appropriate horseradish peroxidase-conjugated secondary antibodies and the SuperSignal West Dura Extended Duration Substrate (Pierce) were used for chemiluminescent detection. After application of chemiluminescent substrate, blots were exposed to standard X-ray film for appropriate lengths of time.
Proliferation and cell cycle distribution analyses
Proliferation of cells were assessed by serial cell counts and by the MTT assay. For cell count assay, 2 Â 10 4 cells were seeded in 12-well plates. Cells were harvested by trypsinization 6 h after initial seeding for the first time point and subsequent time points are indicated (Figure 3a) . Cell counts manually performed in triplicate with a hemocytometer per time point. The MTT assay was performed by standard methods in 96-well dishes. Each well was seeded with 2.5 Â 10 3 cells and allowed to attach overnight before taking first time point. Cells were incubated with 1.2 mM MTT for 4 h at 37 o C in fresh medium and then solubilized overnight with a 1:1 volume of (10% SDS, 10 mM HCl). Optical density at 570 nM was measured on a 96-well spectrophotometer. In experiments where the EGFR inhibitor PD153035 (Tocris Cookson, Ellisville, MO, USA) and the MEK inhibitor U0126 (Calbiochem, EMD Biosciences, San Diego, CA, USA) were used, 7 and 35 mM of drug, respectively, were added to the culture at day 1 after initial seeding of the 96-well dish. For cell cycle distribution, each cell line was seeded at a density of 5 Â 10 5 cells in a 10-cm Petri dish and allowed to attach and grow for 48 h. Plates were assessed to confirm that the cells remain subconfluent and then harvested, fixed and stained with propidium iodide as previously described. Briefly, after trypsinization, cells were washed in phosphate buffered saline (PBS), fixed with ice cold 70% ethanol for 41 h, washed again in PBS and then DNA was quantitatively stained with PBS containing 5 mg/ml propidium iodide and 50 mg/ml RnaseA for 1 h. Cells were evaluated on a flow cytometer (FACScan, Immunocytometry Systems, BD Biosciences, San Jose, CA, USA) and data analysed with the ModFitLT 3.0 software (Immunocytometry Systems, BD Biosciences) for modeling cell cycle distribution.
Clonogenic survival and apoptosis assays
Our standard clonogenic survival assays were performed by seeding the appropriate number of cells in 6-or 10-cm Petri dishes and allowing them to adhere to the plate for o4 h in standard media. Plates were then irradiated with various doses and allowed to grow undisturbed for 10-14 days. Plates were stained with 0.25% crystal violet in 100% methanol to visualize clones that contain at least 50 cells. For clonogenic survival under serum-starved conditions, cells were first allowed to adhere to the plates. The cells were then cultured in media without serum for 24 h, exposed to varying doses of ionizing radiation and returned to full serum media where they were allowed to grow undisturbed for 10-14 days. In the experiment where the PI-3K inhibitor LY294002 (Alexis Biochemicals, San Diego, CA, USA) was used, 25 mM of this agent was added 2 h prior to irradiation. Results were plotted in KaleidaGraph 3.0 (Synergy Software, Reading, PA, USA) with curves generated using a standard linear-quadratic model. The apoptosis assay was performed by measuring fraction of cells with subdiploid DNA content. Briefly, 5 Â 10 5 cells were seeded in 10-cm Petri dishes and allowed to adhere overnight. Cells were then treated with varying doses of radiation and harvested 2 days postirradiation. Again, for apoptosis under serum-starved conditions, the cells were cultured in media with no serum for 24 h before irradiation and returned to full serum media for 2 days before harvesting. Cells were stained with propidium iodide and assayed on a flow cytometer (FACScan, Immunocytometry Systems, BD Biosciences) as described above to determine percent of cells with a subdiploid DNA content. Analysis was performed using the CellQuest 3.0 software (Immunocytometry Systems, BD Biosciences). All irradiation experiments were performed on a Mark I cesium irradiator (J.L. Shepherd and Associates, San Fernando, CA, USA).
Statistical analysis
The Student's t-test was used to assess whether differences in the values of two points are statistically significant. Comparisons were made between the vector controls and EGFRvIII expressing cells at each radiation dose in the clonogenic survival and apoptotic response assays and at each time point in the cell proliferation assays. For the experiment examining the effect of PI-3K inhibition on clonogenic survival (Figure 6 ), comparisons were made between untreated cells versus cells that were treated with LY294002. Differences were considered to be statistically significant with P-values p0.05. All statistical analyses were performed with the software package STATA 3.0 (Computer Resource Center, Santa Monica, CA, USA). Abbreviations EGFR, epidermal growth factor receptor; PI-3K phosphatidylinositol-3 kinase|GBM, glioblastoma multiforme; hTERT, human telomerase; LT, large T antigen; NHA, normal human astrocyte; NHF, normal human fibroblast; EGF, epidermal growth factor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide.
